Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure

Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners

Lupin launches liquid fibre Softovac Liquifibre

Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients

Clariant Healthcare debuts in CPhI India

Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India

CII recognized Cadila among Top 50 Innovative Companies in India

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation

Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion

Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid

FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting

ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346

First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes

Pfizer presents marstacimab Phase 3 Data at ASH 2023

Demonstrate significant bleed reduction in hemophilia A and B